| Date | Title | Description | Source |
| 08.12.2023 | uniQure Announces Inducement Grants Under Nasdaq Listing Rul... | LEXINGTON, Mass. and AMSTERDAM, Dec. 08, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a lea... | einpresswi... |
| 26.06.2023 | uniQure Announces Leadership Addition to Support Advancement... | ~ Walid Abi-Saab, M.D., appointed Chief Medical Officer, will bring extensive track record in leadin... | einpresswi... |
| 20.06.2023 | uniQure announces achievement of $100 million milestone rela... | - | globenewsw... |
| 15.05.2023 | uniQure Announces Sale of Royalty Interest in HEMGENIX® for ... | - | globenewsw... |
| 31.01.2023 | uniQure and Apic Bio enter into global licensing agreement f... | /EIN News/ -- ~ License of APB-102 further strengthens uniQure’s pipeline of innovative gene therap... | einpresswi... |
| 20.12.2022 | uniQure Announces Inducement Grants Under Nasdaq Listing Rul... | /EIN News/ -- LEXINGTON, Mass. and AMSTERDAM, Dec. 20, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ... | einpresswi... |
| 29.11.2022 | uniQure Highlights Therapeutic Potential of AMT-260 in Refra... | /EIN News/ -- ~ IND Submission and Clinical Development Expected to Begin in 2023 ~
~ Advancements ... | einpresswi... |
| 11.10.2022 | uniQure Announces Multiple Presentations at the Upcoming Ann... | LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 11, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NAS... | globenewsw... |
| 03.10.2022 | uniQure to Participate in Upcoming Industry Conferences in O... | LEXINGTON, Mass. and AMSTERDAM, Oct. 03, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a lea... | globenewsw... |
| 06.09.2022 | uniQure to Participate in Upcoming Industry Conferences in S... | LEXINGTON, Mass. and AMSTERDAM, Sept. 06, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a le... | globenewsw... |
| 08.08.2022 | uniQure Announces Second Quarter 2022 Financial Results and ... | ~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington’s disease showed the inv... | globenewsw... |
| 23.06.2022 | uniQure Announces Update on Low-Dose Cohort in Phase I/II Cl... | ~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated... | globenewsw... |
| 22.06.2022 | uniQure Announces Inducement Grants Under Nasdaq Listing Rul... | LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NAS... | globenewsw... |
| 22.06.2022 | CORRECTION -- uniQure Announces Inducement Grants Under Nasd... | LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 (GLOBE NEWSWIRE) -- In a release issu... | globenewsw... |
| 24.05.2022 | uniQure Announces FDA Acceptance of Biologics License Applic... | LEXINGTON, Mass. and AMSTERDAM, May 24, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a lead... | globenewsw... |
| 11.05.2022 | uniQure Announces Inducement Grants Under Nasdaq Listing Rul... | LEXINGTON, Mass. and AMSTERDAM, May 11, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a lead... | globenewsw... |
| 02.05.2022 | uniQure Announces Multiple Presentations at Upcoming America... | LEXINGTON, Mass. and AMSTERDAM, May 02, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a lead... | globenewsw... |
| 02.05.2022 | uniQure Announces First Quarter 2022 Financial Results and H... | ~ Partner CSL Behring submitted Marketing Authorization Application (MAA) in Europe for
etranacogene... | globenewsw... |
| 21.03.2022 | uniQure Announces Completion of Patient Enrollment in the Fi... | LEXINGTON, Mass. and AMSTERDAM, March 21, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a le... | globenewsw... |
| 25.02.2022 | uniQure Announces 2021 Financial Results and Highlights Rece... | ~ Data from largest gene therapy study in hemophilia B showed sustained therapeutic effect at 18-mon... | globenewsw... |
| 07.02.2022 | uniQure Announces Dosing of First Patients in European Open-... | LEXINGTON, Mass. and AMSTERDAM, Feb. 07, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a lea... | globenewsw... |
| 04.02.2022 | EAHAD 2022 - Final Analysis from the Pivotal Phase 3 HOPE-B ... | FINAL ANALYSIS FROM THE PIVOTAL PHASE 3 HOPE-B GENE THERAPY TRIAL: STABLE STEADY-STATE EFFICACY AND ... | marketscre... |
| 16.12.2021 | uniQure Announces Clinical Update on First Patients in Phase... | ~ Treatment was well tolerated with no significant safety issues
related to AMT-130 in first two tr... | marketscre... |
| 16.12.2021 | uniQure Announces Clinical Update on First Patients in Phase... | ~ Treatment was well tolerated with no significant safety issues
related to AMT-130 in first two tr... | globenewsw... |
| 09.12.2021 | uniQure and CSL Behring Announce Primary Endpoint Achieved i... | ~ Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annuali... | marketscre... |
| 09.12.2021 | uniQure and CSL Behring Announce Primary Endpoint Achieved i... | ~ Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annuali... | globenewsw... |
| 02.11.2021 | uniQure Announces Latest Positive Recommendation from Data S... | ~ No Significant Safety Concerns Observed in First Four Patients Enrolled in Higher-dose Cohort ~
~... | globenewsw... |
| 01.11.2021 | uniQure to Participate in Upcoming Industry Conferences in N... | LEXINGTON, Mass. and AMSTERDAM, Nov. 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a lea... | globenewsw... |
| 25.10.2021 | uniQure Announces Third Quarter 2021 Financial Results and H... | ~ Completed 78-week follow-up for hemophilia B pivotal study, with top-line data expected by year-en... | globenewsw... |
| 21.10.2021 | uniQure Announces the Appointment of Rachelle Jacques to its... | LEXINGTON, Mass. and AMSTERDAM, Oct. 21, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a lea... | globenewsw... |
| 19.10.2021 | uniQure Announces Presentations at the Annual Meeting of The... | LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Oct. 19, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NAS... | globenewsw... |
| 16.07.2021 | ISTH 2021 - 52 Week Efficacy and Safety of Etranacogene Deza... | 52 Week Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Severe or Moderate-
Severe ... | marketscre... |
| 14.07.2021 | ISTH 2021 - Clinical Outcomes in Adults with Hemophilia B Wi... | Clinical Outcomes in Adults with
Hemophilia B With and Without Pre-existing Neutralizing Antibodies... | marketscre... |
| 02.07.2021 | uniQure Announces Presentations at Upcoming International So... | LEXINGTON, Mass. and AMSTERDAM, The Netherlands, July 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NAS... | marketscre... |
| 22.06.2021 | uniQure Announces Positive 52-Week Clinical Data from HOPE-B... | ~ Sustained increases in Factor IX (FIX) levels with mean FIX activity of 41.5 percent of normal in ... | marketscre... |
| 22.06.2021 | uniQure to Acquire Corlieve Therapeutics and Advance its Gen... | ~ Expands uniQure’s Pipeline of Innovative Gene Therapies to Treat Neurological Disorders ~
~ Stren... | marketscre... |
| 22.06.2021 | uniQure updates lead gene therapy’s timeline; acquires Corli... | A hemophilia B gene therapy that uniQure is testing in a pivotal clinical trial is on track for a fi... | medcitynew... |
| 16.06.2021 | UNIQURE N.V.
uniQure Announces Enrollment of First Two Pati... | LEXINGTON, Mass. and AMSTERDAM, The Netherlands, June 16, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NAS... | marketscre... |
| 27.05.2021 | UNIQURE N.V.
uniQure Announces Positive Recommendation to A... | LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 27, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASD... | marketscre... |
| 13.05.2021 | UNIQURE N.V.
uniQure Presents HOPE-B Clinical Data Demonstr... | ~ Data Show No Clinically Significant Correlation Between Pre-Existing NAbs and FIX Activity ~
~ Fu... | marketscre... |
| 13.05.2021 | UNIQURE N.V.
ASGCT 2021 - Clinical Outcomes in Patients Wit... | Clinical Outcomes in Patients With and Without Pre-existing
Neutralizing Antibodies to the Vector:
... | marketscre... |
| 06.05.2021 | UNIQURE N.V.
uniQure announces closing of commercialization... | LEXINGTON, Mass. and AMSTERDAM, May 06, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a lead... | marketscre... |
| 28.04.2021 | UNIQURE N.V.
uniQure Announces Presentations at Upcoming Am... | LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 28, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NA... | marketscre... |
| 26.04.2021 | UNIQURE N.V.
uniQure Announces FDA Removes Clinical Hold on... | LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 26, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NA... | marketscre... |
| 13.04.2021 | Huntington’s community grieves not just one therapeutic setb... | For the community of people affected by Huntington’s disease — a group that is no stranger to disapp... | statnews.c... |
| 08.04.2021 | UNIQURE N.V.
uniQure Announces Publications of Preclinical ... | LEXINGTON, Mass. and AMSTERDAM, April 08, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a le... | marketscre... |
| 05.04.2021 | UNIQURE N.V.
uniQure Announces Completion of Enrollment in ... | ~ Enrollment of second dose cohort expected to begin in 3Q 2021 ~
~ Company announces plans to init... | marketscre... |
| 29.03.2021 | UNIQURE N.V.
uniQure Announces Findings from Reported Case ... | ~ Independent investigation shows that etranacogene dezaparvovec is highly unlikely to be the cause
... | marketscre... |
| 01.03.2021 | uniQure Announces 2020 Financial Results and Highlights Rece... | ~ Six patient procedures now completed in Phase I/II for Huntington’s disease, including two procedu... | globenewsw... |
| 26.02.2021 | uniQure to Participate in Multiple Upcoming Industry Confere... | LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 26, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NAS... | globenewsw... |
| 25.06.2020 | CSL Behring, uniQure in $2B deal to in-license hemophilia ge... | A Dutch biotech company developing a gene therapy for hemophilia has made a deal with the U.S.-based... | medcitynew... |
| 04.12.2019 | Top 8 Predictions That Will Disrupt Healthcare in 2020 | Every year, our team of futurists, analysts, and consultants at Frost & Sullivan's Transformatio... | forbes.com... |
| 31.07.2017 | Even With High Costs & Uncertainty, Gene Therapy Finds F... | 8 Shares Email Facebook Twitter LinkedIn
This is the first entry of the Homo Posterius (“the Next H... | news.crunc... |
| 30.01.2017 | uniQure wins a BTD for hemophilia B therapy; Allergan... | • The Dutch biotech uniQure has picked up a breakthrough drug designation from the FDA for AMT-0... | endpts.com... |
| 12.09.2016 | With small RetroSense deal, Allergan hoping for big win | RP is a group of congenital retinal diseases driven by mutations in the rhodopsin gene. The disease ... | medcitynew... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
| 08.06.2015 | Five (non-cancer) areas Bristol-Myers Squibb is pursuing har... | The pharma giant has indeed found a sweet spot in immuno-oncology. Take a look at the recent success... | medcitynew... |
| 01.07.2014 | uniQure Secures Additional $10M Venture Loan from Hercules C... | uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the closing of an addit... | forbion.co... |
| 13.11.2013 | GeNO, uniQure look to leap through biotech IPO window in Q4 ... | Waltham, MA-based GeNO is throwing its hat into a crowded biotech IPO ring, looking to raise $50 mil... | fiercebiot... |
| 22.05.2013 | uniQure and consortium to receive EUR 2.5 million Eurostars ... | uniQure B.V., a leader in the field of human gene therapy, today announced that with its consortium ... | forbion.co... |
| 27.07.2012 | Fundraising: Gene therapy firm targeting sickle cell anemia ... | Product: Gene therapy to target sickle cell anemia, beta-thalassemia and childhood cerebral adrenole... | medcitynew... |
| - | Fundraising: Gene therapy firm targeting sickle cell anemia ... | Company name: bluebird bio.
Industry: Biotechnology.
Location: Cambridge, Massachusetts.
Product:... | medcitynew... |
| - | CSL Behring, uniQure in $2B deal to in-license hemophilia ge... | A Dutch biotech company developing a gene therapy for hemophilia has made a deal with the U.S.-based... | medcitynew... |
| - | uniQure updates lead gene therapy’s timeline; acquires Corli... | A hemophilia B gene therapy that uniQure is testing in a pivotal clinical trial is on track for a fi... | medcitynew... |
| - | With small RetroSense deal, Allergan hoping for big win | Allergan’s recent deal for gene therapy company RetroSense Therapeutics, based in Ann Arbor, Michiga... | medcitynew... |
| - | Five (non-cancer) areas Bristol-Myers Squibb is pursuing har... | Outside of cancer immunotherapy, Bristol-Myers Squibb is interested in pursuing five areas: Heart fa... | medcitynew... |
